Physician profile
Rodney K Ison
NPI 1235114174
$9,675.36
in general payments reported to CMS, 2019-2025
43 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 91% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,258 · 2020: $978 · 2021: $1,823 · 2022: $1,637 · 2023: $1,677 · 2024: $1,173 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,885 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,884.80 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,101.86 | 2021-2025 | |
| Novo Nordisk INC | $1,085.78 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $930.45 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $785.14 | 2019-2025 | |
| Glaxosmithkline, LLC. | $755.70 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $659.78 | 2020-2025 | Jardiance, Synjardy, Ofev |
| Merck Sharp & Dohme LLC | $611.54 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Astellas Pharma US INC | $412.21 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $385.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $193.72 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $190.51 | 2019-2025 | Spravato |
| Biohaven Pharmaceuticals, INC. | $190.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $176.65 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.21 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.09 | 2021-2025 | Xifaxan |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $160.36 | 2022 | |
| Amarin Pharma, INC. | $157.07 | 2019-2022 | |
| Abbott Laboratories | $156.64 | 2024-2025 | Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $153.49 | 2020-2023 | |
| Sanofi Pasteur INC. | $142.49 | 2019-2023 | |
| Genentech USA, INC. | $118.76 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $100.10 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $94.65 | 2023-2024 | Gvoke Hypopen |
| Corcept Therapeutics | $83.92 | 2020-2023 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $82.22 | 2020-2022 | |
| Axsome Therapeutics, INC. | $78.14 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $62.05 | 2023 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $47.25 | 2020-2024 | Nexletol |
| Idorsia Pharmaceuticals US INC | $45.76 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $42.98 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $39.77 | 2023 | Prehevbrio |
| Dexcom, INC. | $39.46 | 2023-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $38.88 | 2023 | Gemtesa |
| Allergan, INC. | $38.58 | 2020 | |
| Organon LLC | $32.25 | 2025 | Nexplanon |
| Seqirus USA INC | $27.51 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Exact Sciences Corporation | $20.75 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $19.61 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.35 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $14.33 | 2022 | |
| Ascensia Diabetes Care US INC. | $13.58 | 2025 | |
| Inogen, INC. | $13.39 | 2022 | |
| Shire North American Group INC | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Ison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.